



(51) International Patent Classification:

C12N 9/24 (2006.01) G01N 33/573 (2006.01)
A61K 38/47 (2006.01) G01N 33/68 (2006.01)
C07K 14/315 (2006.01)

(21) International Application Number:

PCT/EP2012/067841

(22) International Filing Date:

12 September 2012 (12.09.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1115841.7 13 September 2011 (13.09.2011) GB

(71) Applicant (for all designated States except US): GENOV-
IS AB [SE/SE]; PO Box 790, S-220 07 Lund (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): NIZET, Victor [US/US]; 13167 Sunstone Pointe, San Diego, California 92130 (US). HOLLANDS, Andrew [AU/US]; Department of Pediatrics, USCD School of Medicine, 9500 Gilman Drive, La Jolla, California 92093-0687 (US). COLLIN, Mattias [SE/SE]; Department of Clinical Sciences, Division of Infection Medicine, Biomedical Center B14, Sölvegatan 19, Lund University S-223 62 Lund (SE). ALLHORN, Maria [SE/SE]; Department of Clinical Sciences, Division of Infection Medicine, Biomedical Center B14, Sölvegatan 19, Lund University S-223 62 Lund (SE). SJÖGREN, Jonathan [SE/SE]; Department of Clinical Sciences, Division of Infection Medicine, Biomedical Cen-

ter B14, Sölvegatan 19, Lund University S-223 62 Lund (SE).

(74) Agent: ROQUES, Sarah Elizabeth; 14 South Square, Gray's Inn, London, Greater London WC1R 5JJ (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: ENDOGLYCOSIDASE FROM STREPTOCOCCUS PYOGENES AND METHODS USING IT

Figure 2.



(57) Abstract: The invention provides an endoglycosidase, referred to as EndoS49 and having the amino acid sequence of SEQ ID NO: 1. EndoS49 was isolated from Streptococcus pyogenes strain NZ131 and is a homologue of EndoS. EndoS49 has specific endoglycosidase activity on native IgG and cleaves a larger variety of Fc glycans than EndoS. A mutant thereof where the glutamic acid at position 186 of SEQ ID NO: 1 was substituted was produced: said mutant lacks endoglycosidase activity but is capable of binding to IgG. Methods using EndoS49, deletions thereof and said mutant, especially for assessing glycosylation of IgG or for isolating IgG are disclosed.